SG Americas Securities LLC Invests $133,000 in Alector, Inc. (NASDAQ:ALEC)

SG Americas Securities LLC acquired a new stake in shares of Alector, Inc. (NASDAQ:ALEC) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 16,726 shares of the company’s stock, valued at approximately $133,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ALEC. Barclays PLC grew its holdings in shares of Alector by 24.0% during the third quarter. Barclays PLC now owns 138,826 shares of the company’s stock valued at $899,000 after buying an additional 26,856 shares during the last quarter. Euclidean Capital LLC boosted its stake in Alector by 33.3% during the 3rd quarter. Euclidean Capital LLC now owns 1,307,858 shares of the company’s stock valued at $8,475,000 after purchasing an additional 326,964 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Alector by 33.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 778,077 shares of the company’s stock valued at $5,042,000 after purchasing an additional 195,411 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Alector by 68.2% in the third quarter. Acadian Asset Management LLC now owns 153,266 shares of the company’s stock worth $993,000 after purchasing an additional 62,155 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its position in shares of Alector by 64.8% during the third quarter. Hsbc Holdings PLC now owns 36,807 shares of the company’s stock valued at $241,000 after buying an additional 14,472 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $41.00 target price on shares of Alector in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Alector Stock Performance

ALEC stock opened at $5.07 on Thursday. The company has a market cap of $485.45 million, a price-to-earnings ratio of -3.27 and a beta of 0.79. The business’s 50-day moving average is $6.23 and its two-hundred day moving average is $6.21. Alector, Inc. has a fifty-two week low of $3.66 and a fifty-two week high of $9.06.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.31. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. The company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $8.35 million. Equities analysts predict that Alector, Inc. will post -1.85 earnings per share for the current year.

Insider Transactions at Alector

In related news, CEO Arnon Rosenthal sold 18,837 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $130,352.04. Following the transaction, the chief executive officer now directly owns 2,000,380 shares of the company’s stock, valued at approximately $13,842,629.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Arnon Rosenthal sold 18,837 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $130,352.04. Following the completion of the transaction, the chief executive officer now directly owns 2,000,380 shares in the company, valued at approximately $13,842,629.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Marc Grasso sold 5,716 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $39,554.72. Following the sale, the chief financial officer now owns 144,957 shares in the company, valued at approximately $1,003,102.44. The disclosure for this sale can be found here. Insiders have sold 30,554 shares of company stock worth $211,434 in the last 90 days. 14.00% of the stock is currently owned by insiders.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.